Search
Avelumab
go.drugbank.com/drugs/DB11945ApprovedInvestigational[A261496] Avelumab was first approved by the FDA on March 23, 2017. … [A261496] On September 18 and December 18 of the same year, it was also granted approval by EMA [L48126] and Health Canada,[L48171] respectively.
Products: BAVENCIO CONCENTRATE FOR SOLUTION FOR INFUSION 200MG/10MLMosunetuzumab
go.drugbank.com/drugs/DB15434ApprovedInvestigational[A249320,A249390] Mosunetuzumab has the potential to circumvent resistance to [rituximab] in patients with follicular lymphoma,[A249320,L42230] and unlike CAR-T therapies such as [axicabtagene ciloleucel … [L44562] and in December 2025, the subcutaneous formulation was approved for the same indication. [L54848]
Tocofersolan
go.drugbank.com/drugs/DB11635ApprovedIn addition to the above, tocofersolan has been studied as a promising application as an absorption enhancer in drug delivery [MSDS]. … D-Alpha-tocopheryl polyethylene glycol 1000 succinate (Tocofersolan, Vedrop), has been developed in Europe as an orally bioavailable source of vitamin E in children suffering from cholestasis [L2371].
Erythropoietin
go.drugbank.com/drugs/DB00016ApprovedInvestigationalEpoetin alfa (Epoge) was developed by Amgen Inc. in 1983 as the first rhEPO commercialized in the United States, followed by other alfa and beta formulations. … It has a molecular weight of approximately 30,400 daltons and is produced by mammalian cells into which the human erythropoietin gene has been introduced.
Bisoctrizole
go.drugbank.com/drugs/DB11262ApprovedBisoctrizole, or methylene bis-benzotriazolyl tetramethylbutylphenol, is a broad-spectrum organic UV filter that is marketed as Tinosorb M [A19212]. … Bisoctrizole is not approved by the FDA, but is approved in the EU and other parts of the world as a UV-filter in sunscreens, day care products and skin lightening products at a maximum concentration of
Asparaginase Erwinia chrysanthemi
go.drugbank.com/drugs/DB08886ApprovedInvestigational: it has been used as part of multi-agent chemotherapy. … [L149] In June 2021, the recombinant form of asparaginase _Erwinia chrysanthemi_ was approved by the FDA as a component of a chemotherapy regimen to treat acute lymphoblastic leukemia and lymphoblastic
Ancestim
go.drugbank.com/drugs/DB09103ApprovedWithdrawnAncestim was developed by Amgen and sold to Biovitrium in December 2008. It was submitted to the FDA under the status of recommendation for approval with a 10 to 1 votes. … [T68] It was also approved by Health Canada in 1999 but it is currently under the status of canceled post-market.[L1087]
Altretamine
go.drugbank.com/drugs/DB00488ApprovedWithdrawnAn alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects.
Esketamine
go.drugbank.com/drugs/DB11823ApprovedInvestigational[L5596,A175462] On March 5, 2019, the nasal spray drug, _esketamine_, also known as _Spravato_ (by Janssen Pharmaceuticals), was approved by the FDA for treatment-resistant major depression. … This is the first time that the FDA has approved esketamine for any use. The FDA approved ketamine (Ketalar) in 1970.
Lecanemab
go.drugbank.com/drugs/DB14580ApprovedInvestigational[A253962,L44547] On January 6, 2023, lecanemab was granted accelerated approval by the FDA for the treatment of Alzheimer’s Disease.[L44547] It was granted full FDA approval on July 6, 2023.